Cetilistat

Cetilistat is an inhibitor of pancreatic lipase (IC50s = 5.95 and 54.8 nM for the human and rat enzymes, respectively).1 It reduces increases in plasma triglyceride levels in an oral fat tolerance test, indicating decreased intestinal fat absorption, in rats when administered at a doses ranging from 3 to 100 mg/kg. Dietary administration of cetilistat (4.9-50.7 mg/kg per day) decreases body weight gain without affecting food intake, as well as reduces increases in plasma triglyceride and leptin levels in a rat model of high-fat diet-induced obesity. It also reduces viral load in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC90 = 2.9 µM) and inhibits SARS-CoV-2 replication in a plaque reduction assay (EC50 = 1.13 µM).2WARNING This product is not for human or veterinary use.

A pancreatic lipase inhibitor

401.6

≥95%

Biochemicals/Antivirals/Small Molecule Inhibitors

Formal_Name:2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one;Synonyms:ATL-962

O=C1OC(OCCCCCCCCCCCCCCCC)=NC2=C1C=C(C)C=C2

C25H39NO3

282526-98-1

≥ 4 years

Acetonitrile: slightly soluble DMSO: slightly soluble